Engineered immune cells take on lupus kidney disease
Disease control
Not yet recruiting
This phase 2 trial is testing a new treatment called FT819 for people with lupus nephritis, a serious kidney complication of lupus. FT819 is made from donor immune cells that are engineered to target and destroy faulty B cells. The study will enroll 53 participants and aims to se…
Phase: PHASE2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC